8-K: HeartSciences Expands Equity Plan, Grants Executive Awards

HeartSciences Inc. announced an amendment to its 2023 Equity Incentive Plan, increasing the share pool to 1.25 million and granting restricted shares and RSUs to key executives and directors.

Summary

• The Board of Directors approved Amendment No. 3 to the 2023 Equity Incentive Plan on November 28, 2025.
• The maximum aggregate number of shares available under the Plan increased from 1,000,000 to 1,250,000 shares of common stock.
• The Plan also includes an automatic annual increase mechanism, adding shares equal to the lesser of 25% of outstanding stock or a lower number determined by the Administrator, starting May 1, 2026.
• The Plan Amendment is subject to shareholder approval at the Company's next annual meeting.
• Equity Awards (restricted shares and Restricted Stock Units, RSUs) were granted to executive officers, non-employee directors, and employees.
• CEO Andrew Simpson received 70,000 restricted shares of Common Stock.
• COO Mark Hilz received 45,000 RSUs.
• CFO Danielle Watson received 15,000 RSUs.
• Each non-employee director received 15,000 RSUs.
• Vesting for executives and non-employee directors is generally over 2-3 years, subject to continuous service and shareholder approval of the Plan Amendment.
• All equity awards will immediately vest if the Company achieves $250,000 or more in revenue in any fiscal quarter ending after the date of this Current Report.

Sentiment

Score: 6

Explanation: The expansion of the equity plan and grants to management are generally positive for incentivizing leadership and aligning interests. However, the need for shareholder approval and the potential for dilution from the evergreen provision introduce some uncertainty and a moderate negative aspect.

Positives

• Incentivizes key management and directors through equity awards, aligning their interests with shareholders.
• The performance-based vesting condition (achieving $250,000 in quarterly revenue) provides a clear target for management.
• The increased share pool allows for future equity grants to attract and retain talent.

Negatives

• The Plan Amendment and the awards are subject to shareholder approval, introducing uncertainty.
• Potential for shareholder dilution due to the increased number of shares available for issuance under the equity plan (1,250,000 shares plus the evergreen provision).
• The 'evergreen' provision (up to 25% of outstanding stock annually) could lead to significant future dilution if not managed carefully.

Risks

• Failure to obtain shareholder approval for the Plan Amendment could invalidate the recent equity awards and limit future incentive capabilities.
• Significant dilution of existing shareholders if a large number of shares are issued under the expanded plan, especially with the 25% evergreen provision.
• The Company's ability to achieve the $250,000 quarterly revenue target for accelerated vesting is uncertain.

Future Outlook

The company aims to incentivize its leadership and employees through equity, with a clear performance target of $250,000 in quarterly revenue to accelerate vesting, signaling a focus on growth.

Management Comments

• The offering and issuance of the Equity Awards will be exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, or Rule 506(b) of Regulation D promulgated thereunder, and/or Rule 701 promulgated thereunder and applicable state securities laws.

Industry Context

Equity incentive plans are a standard practice across industries, particularly in growth-oriented companies, to attract, retain, and motivate key personnel by aligning their financial interests with long-term company performance and shareholder value. The performance-based vesting tied to revenue suggests a focus on commercialization and market penetration, common for companies in the medical device or health tech space.

Comparison to Industry Standards

• N/A. This filing primarily details internal compensation and governance changes rather than operational or financial results that can be directly compared to specific industry benchmarks or competitors' project outcomes.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the increased share pool and evergreen provision; however, incentivized management could lead to increased shareholder value. Shareholder approval is required for the plan amendment.
• Employees: Equity awards provide a significant incentive for retention and performance.
• Management/Directors: Direct financial benefit through restricted shares and RSUs, aligning their interests with company performance.

Next Steps

• Shareholders will consider and vote upon the Plan Amendment at the Company's next annual meeting of shareholders.
• RSUs will be promptly granted.
• Vesting of restricted shares and settlement of RSUs will occur based on specified conditions, including continuous employment/service and potential performance targets.

Key Dates

Recommendation

The filing indicates a standard corporate action to incentivize management and directors through an expanded equity plan. While the grants and performance-based vesting are positive for aligning interests, the need for shareholder approval and the potential for future dilution from the evergreen provision introduce a degree of uncertainty. Without further operational or financial updates, a 'hold' recommendation is appropriate, awaiting shareholder vote outcomes and clearer indications of the company's growth trajectory and financial performance.

Keywords

HeartSciences Inc., HSCS, Equity Incentive Plan, Restricted Stock Units, RSUs, Stock Awards, Executive Compensation, Corporate Governance, Shareholder Approval, Dilution, SEC Filing, 8-K, Compensation Plan, Revenue Target